Home / Market Reports / Medical Care / Global Latent Tuberculosis Infection (LTBI) Testing Market Growth (Status and Outlook) 2023-2029

Global Latent Tuberculosis Infection (LTBI) Testing Market Growth (Status and Outlook) 2023-2029

Global Latent Tuberculosis Infection (LTBI) Testing Market Growth (Status and Outlook) 2023-2029

Product Code:460080

Published Date: Feb 08,2023

Pages: 87

Region: Global

Category: Medical Care

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

SELECT A FORMAT

ADD TO BASKET

BUY NOW

Provide comprehensive and accurate analysis and reports according to your exact requirements

Provide comprehensive and accurate analysis and reports according to your exact requirements

CONTACT US 

The Latent Tuberculosis Infection (LTBI) Testing industry can be broken down into several segments, Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA), etc.

Across the world, the major players cover Qiagen, Oxford Immunotec, Sanofi, etc.

Diagnosing and treating latent tuberculosis (TB) infection (LTBI) is recognized by the World Health Organization as an important strategy to accelerate the decline in global TB and achieve TB elimination. Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active tuberculosis (TB). Diagnosis and treatment for LTBI are important for TB, especially in high-risk populations. Tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are used to diagnose LTBI.

LPI (LP Information)' newest research report, the “Latent Tuberculosis Infection (LTBI) Testing Industry Forecast” looks at past sales and reviews total world Latent Tuberculosis Infection (LTBI) Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected Latent Tuberculosis Infection (LTBI) Testing sales for 2023 through 2029. With Latent Tuberculosis Infection (LTBI) Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Latent Tuberculosis Infection (LTBI) Testing industry.

This Insight Report provides a comprehensive analysis of the global Latent Tuberculosis Infection (LTBI) Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Latent Tuberculosis Infection (LTBI) Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Latent Tuberculosis Infection (LTBI) Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Latent Tuberculosis Infection (LTBI) Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Latent Tuberculosis Infection (LTBI) Testing.

The global Latent Tuberculosis Infection (LTBI) Testing market size is projected to grow from US$ 1365.6 million in 2022 to US$ 2000 million in 2029; it is expected to grow at a CAGR of 5.6% from 2023 to 2029.

The detection industry of latent tuberculosis infection (LTBI) can be subdivided into several parts: tuberculin skin test (TST), interferon release test (IGRA), etc.

Globally, there are mainly Qiagen, Oxford Immunotec, Sanofi, etc.

Diagnosing and treating latent tuberculosis infection (LTBI) is an important strategy recognized by the World Health Organization to accelerate the decline of global tuberculosis and achieve the elimination of tuberculosis. Latent tuberculosis infection (LTBI) refers to the state of continuous immune response to the stimulation of Mycobacterium tuberculosis antigen in the absence of clinical evidence of active tuberculosis (TB). The diagnosis and treatment of long-term tuberculosis is very important for tuberculosis, especially for high-risk groups. Tuberculin skin tests (TST) and interferon release tests (IGRAs) were used to diagnose LTBI.

This report presents a comprehensive overview, market shares, and growth opportunities of Latent Tuberculosis Infection (LTBI) Testing market by product type, application, key players and key regions and countries.

Market Segmentation:
Segmentation by type
    Tuberculin Skin Test (TST)
    Interferon Gamma Released Assay (IGRA)

Segmentation by application
    Hospitals and Clinics
    Diagnostic Laboratories
    Others

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
    Qiagen
    Sanofi
    Oxford Immunotec
    Thermo Fisher Scientific
    Par Sterile
    Bio-Rad Laboratories